P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.

P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.

Drug Resistant Malaria Due to Plasmodium Falciparum

Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.

Artesunate (AS) group

Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.

DHA - PPQ group

Chu R Cam commune

P. Falciparum Resistance to Artemisinin in Vietnam

Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam

Median parasite clearance time (total hours) in both arms (by light microscopy (LM) and quantitative real time PCR (qPCR)) will be computed using the 12-hourly parasite density measurements from day0 till parasite clearance. Parasite clearance time (in hours) will be computed using the Parasite Clearance Estimator tool available online (http://www.wwarn.org/toolkit/data-management/parasite-clearance-estimator).

This outcome is measured at day 28 and 42 of follow-up. Treatment outcomes such as ACPR, early or late clinical failures are defined following WHO guidelines;

Individual and mean IC50 and IC90 values will be computed for each drug using the IVART tool available online (http://www.wwarn.org/tools-resources/toolkit/analyse/ivart)

asexual and sexual parasite forms will be detected by quantitative qPCR and reverse transcription real time PCR (rtPCR), respectively. This outcome will be measured for each sampling time point.

All parasites at day0, and day3 for patients with delayed clearance, will be genotyped for molecular markers of artemisinin resistance (K13 mutations) following a published protocol.

National Institute of Malariology, Parasitology and Entomology, Vietnam

Institute of Tropical Medicine, Belgium

Supplement of flaxseed powder (60 g/day)during 12 weeks

Placebo powder supplement 60 g/day during 12 weeks

Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks

Safflower oil 30 ml/day (no ALA) during 12 weeks

Morbid Obesity

Atherosclerosis

Systemic Inflammation

Placebo

Alpha-linolenic acid/ALA

Alpha linolenic acid/ALA

Hospital das Clinicas-ICHC-9th Floor- Av. Eneias C. Aguiar 255

Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation

Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic Acid

Joel Faintuch

Associate Professor, Department of Gastroenterology, Sao Paulo University Medical School

University of Sao Paulo

Malaria in Pregnancy

HIV Infections

sulfadoxine-pyrimethamine intermittent preventive treatment

chloroquine

DBL-Centre for Health Research and Development

Uganda AIDS Commission

Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda

Influence of HIV Infection on the Effectiveness of Malaria Prevention During Pregnancy, With Emphasis on the Effect of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda

manihot esculenta/febre

P. Falciparum Resistance to Artemisinin in Vietnam

Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation

Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda

O mais completo banco de dados de ervas medicinais apoiado pela ciência